RegenxBio Inc

Overview

RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC, is a clinical-stage biotechnology company. It discovers and develops gene therapy for the treatment of various retinal, metabolic, and neurodegenerative diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. RegenxBio's products include AAV plasmids, AAV vector reporter systems and custom AAV vectors. The company’s gene therapy product candidates deliver genes to cells for addressing genetic defects and enable cells in the body to produce therapeutic proteins or antibodies that act on the disease. RegenxBio employs its proprietary NAV technology platform, a gene delivery technology, to advance its product candidates. RegenxBio is headquartered in Rockville, Maryland, the US.
Key Stats
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, Maryland
Headquarters

United States of America

Contact

1 240 5528181

Website
regenxbio.com
No of Employees

306

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

RGNX [NASD]

Revenue (2020)

$155 m

340% (2020 vs 2019)
Net Income (2020)

$-111 m

-17.2% (2020 vs 2019)
Net Profit Margin

-72 %

73.2% (2020 vs 2019)
Market Cap *

$1,426 m

EPS *

$-3

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters RegenxBio IncTakeda Pharmaceutical Co LtdAmgen IncRegeneron Pharmaceuticals Inc
Key Information
Headquarters United States of America Japan United States of America United States of America
Headquarter City ROCKVILLE CHUO-KU THOUSAND OAKS TARRYTOWN
Headquarter State/Province Maryland Tokyo California New York
No. of Employees 306 47,099 24,300 9,123
Entity Type Public Public Public Public

Products & Services

RegenxBio is a biotechnology company that discovers and develops gene therapy for the treatment of various retinal, metabolic, and neurodegenerative diseases. Key products and services offered by the company include the following:

Products
  • Pipeline RGX-501:
  • Homozygous Familial Hypercholesterolemia
  • RGX-111:
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • REGENXBIO
  • NAV
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Allan M. Fox Chairman Executive Board 2020 72 Mr. Allan M. Fox has been the Chairman of the company since 2020. He has been a member of the...
Steve Pakola, M.D. Chief Medical Officer; Senior Vice President Senior Management 2019 - Dr. Steve Pakola has been the Senior Vice President and Chief Medical Officer of the company since 2019. Prior to...
Olivier Danos, Ph.D. Senior Vice President; Chief Scientific Officer Senior Management 2017 63 Dr. Olivier Danos has been the Senior Vice President and Chief Scientific Officer of the company since 2017. Prior to...
Curran M. Simpson Senior Vice President - Product Development; Chief Technology Officer Senior Management 2015 59 Mr. Curran M. Simpson is the Chief Technology Officer and Senior Vice President of Product Development of the company. Prior...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2019 Regulatory Approval In January, RegenxBio obtained Rare Pediatric Disease designation from the FDA for its RGX-181, a…
2019 Regulatory Approval In May, the company's licensed product, Zolgensma, obtained the FDA approval as a one-time infusion…
2019 Contracts/Agreements In July, RegenxBio signed an exclusive license, development and commercialization agreement with Neurimmune AG pursuant…
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Regenxbio EU Ltd

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
06 Jan 2021 REGENXBIO Raises USD230.3 Million in Public Offering of Shares Equity Offering RegenxBio Inc
22 Dec 2020 Healthcare Royalty Management to Acquire Zolgensma Royalties from REGENXBIO Asset Transaction Healthcare Royalty Management LLC RegenxBio Inc
02 May 2020 Abeona Therapeutics Terminates Licensing Agreement with RegenxBio Licensing Agreement Abeona Therapeutics Inc RegenxBio Inc
31 Mar 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
04 Sep 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
31 Jul 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

39

Active Jobs

15

Posted

4

Closed

Job Trends

Latest Jobs

Job title Company Country
Scientist/Senior Scientist, Target Discovery (AAV Biology/Systemic Gene Therapy) RegenxBio Inc United States
Scientist, Target Discovery (Ocular Gene Therapy) RegenxBio Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar